TSKF To Enter Consumer Health Sector In China
This article was originally published in PharmAsia News
Executive SummaryGlaxoSmithKline has mapped out its global strategy to increase investment in the consumer healthcare sector. In line with the direction, GSK's China joint venture TSKF marketed its first dental health product Sensodyne toothpaste in the country late 2008 (PharmAsia News, Oct. 13, 2008). TSKF said that the move represented a strategic expansion from merely an OTC business to consumer health; focus and investment in the core OTC market will continue. The company recently launched a new headache package for its top OTC earner Fenbid to extend the brand. Capturing a quarter of China's analgesics market, Fenbid contributed RMB 500 million ($73 million) to TSKF's total revenue of RMB 1.6 billion in 2008. (Click here for more - Chinese language)
You may also be interested in...
HBW Executive Decisions: HELP Endorses Hahn, Industry Award For AHPA's McGuffin, CHPA, Herbalife Hires
CHPA adds Allgaier to head development, relations; Vetere joins Herbalife as VP, CIO; Hahn's FDA commissioner nomination clears HELP committee; and AHPA's McGuffin recognized as 2019 Industry Leader.
Almost a year after acquiring Loxo Oncology, Lilly is combining its Lilly Research Laboratories staff with a group headed by three top Loxo execs to lead cancer R&D and business development.